209 related articles for article (PubMed ID: 28375785)
1. Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
Haydu LE; Scolyer RA; Lo S; Quinn MJ; Saw RPM; Shannon KF; Spillane AJ; Stretch JR; McCarthy WH; Thompson JF
J Clin Oncol; 2017 May; 35(15):1721-1729. PubMed ID: 28375785
[TBL] [Abstract][Full Text] [Related]
2. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E
Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470
[TBL] [Abstract][Full Text] [Related]
3. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden.
Isaksson K; Katsarelias D; Mikiver R; Carneiro A; Ny L; Olofsson Bagge R
Ann Surg Oncol; 2019 Sep; 26(9):2839-2845. PubMed ID: 31111349
[TBL] [Abstract][Full Text] [Related]
4. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
Haydu LE; Lo SN; McQuade JL; Amaria RN; Wargo J; Ross MI; Cormier JN; Lucci A; Lee JE; Ferguson SD; Saw RPM; Spillane AJ; Shannon KF; Stretch JR; Hwu P; Patel SP; Diab A; Wong MKK; Glitza Oliva IC; Tawbi H; Carlino MS; Menzies AM; Long GV; Lazar AJ; Tetzlaff MT; Scolyer RA; Gershenwald JE; Thompson JF; Davies MA
J Clin Oncol; 2020 May; 38(13):1429-1441. PubMed ID: 31990608
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of the seventh edition American Joint Committee on Cancer staging system for conjunctival melanoma.
Yousef YA; Finger PT
Arch Ophthalmol; 2012 May; 130(5):599-606. PubMed ID: 22652846
[TBL] [Abstract][Full Text] [Related]
6. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
Fujisawa Y; Yoshikawa S; Minagawa A; Takenouchi T; Yokota K; Uchi H; Noma N; Nakamura Y; Asai J; Kato J; Fujiwara S; Fukushima S; Uehara J; Hoashi T; Kaji T; Fujimura T; Namikawa K; Yoshioka M; Murata N; Ogata D; Matsuyama K; Hatta N; Shibayama Y; Fujiyama T; Ishikawa M; Yamada D; Kishi A; Nakamura Y; Shimiauchi T; Fujii K; Fujimoto M; Ihn H; Katoh N
J Dermatol Sci; 2019 May; 94(2):284-289. PubMed ID: 31023613
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
8. The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma.
Bagger M; Andersen MT; Andersen KK; Heegaard S; Andersen MK; Kiilgaard JF
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):438-44. PubMed ID: 25537201
[TBL] [Abstract][Full Text] [Related]
9. External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?
Madu MF; Franke V; Van de Wiel BA; Klop WMC; Jóźwiak K; van Houdt WJ; Wouters MWJM; van Akkooi ACJ
Melanoma Res; 2020 Apr; 30(2):185-192. PubMed ID: 31651715
[TBL] [Abstract][Full Text] [Related]
10. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract][Full Text] [Related]
11. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
12. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
13. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
[TBL] [Abstract][Full Text] [Related]
14. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L
J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399
[TBL] [Abstract][Full Text] [Related]
16. Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.
Ben-Porat L; Panageas KS; Hanlon C; Patel A; Halpern A; Houghton AN; Coit D
Cancer; 2006 Jan; 106(1):163-71. PubMed ID: 16331596
[TBL] [Abstract][Full Text] [Related]
17. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
18. Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases.
Seifried S; Haydu LE; Quinn MJ; Scolyer RA; Stretch JR; Thompson JF
Ann Surg Oncol; 2015; 22(6):1959-66. PubMed ID: 25384702
[TBL] [Abstract][Full Text] [Related]
19. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.
Romano E; Scordo M; Dusza SW; Coit DG; Chapman PB
J Clin Oncol; 2010 Jun; 28(18):3042-7. PubMed ID: 20479405
[TBL] [Abstract][Full Text] [Related]
20. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma.
Helvind NM; Brinch-Møller Weitemeyer M; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
JAMA Dermatol; 2023 Nov; 159(11):1213-1222. PubMed ID: 37650576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
